retatrutide clinical trials near me Demand for Unapproved Weight-Loss Drug Surges on Social Media Starting Phase 3b Clinical Trial

Gathering Your Supplies Before starting, collect all necessary items

Next steps: FDA decision (REDEFINE-1 & 2) expected late 2026 REDEFINE-11 (2.4/2.4 mg) readout in H1 2027 Higher-dose Phase 3 initiation planned H2 2026 Why It Matters: The obesity market is now a high-efficacy battleground, with GLP-1 and dual incretin therapies redefining standards of care

Interestingly, these effects were absent in mice lacking the GLP-1 receptor and in wild-type mice cotreated with a GLP-1 receptor antagonist (30)

[DOI] [PMC free article] [PubMed] [Google Scholar] 185.Bhalla, S., Mehan, S., Khan, A

The thigh also tends to have a consistent subcutaneous fat layer in most body types, making it easier to achieve the correct injection depth

This article explains the expected timeline, the factors that influence individual response, and the current regulatory status of retatrutide in the UK